Pfizer's new cancer combo shows early promise but trial ends early
NCT ID NCT06285097
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 36 times
Summary
This early-stage trial tested a new drug called PF-07820435, alone or with another drug (sasanlimab), in 9 people with advanced solid tumors like lung or skin cancer. The goal was to check safety and see if the drug shrinks tumors. However, the study was terminated, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Corewell Health (reference non-engagement letter)
Grand Rapids, Michigan, 49503, United States
-
Florida Cancer Specialists Sarasota Drug Development Unit
Sarasota, Florida, 34232, United States
-
Hospital Oncologico Dr. Isaac Gonzalez-Martinez
Rio Piedras, 00935, Puerto Rico
-
National Cancer Center Hospital East
Kashiwa, Chiba, 277-8577, Japan
-
Pan American Center for Oncology Trials, LLC
Rio Piedras, 00935, Puerto Rico
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
Sarah Cannon Research Institute - Pharmacy
Nashville, Tennessee, 37203, United States
-
The Cancer Institute Hospital of JFCR
Koto, Tokyo, 135-8550, Japan
-
Tristar Centennial Medical Center
Nashville, Tennessee, 37203, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PF-07820435 (immune agonist) and sasanlimab (PD-1 blocker)
What this could lead to
If successful, this could point toward a new treatment option for advanced solid tumors like lung or skin cancer.
What could go wrong
This is a very early (Phase 1) trial with only 9 participants, so results may not apply broadly. The study was terminated, meaning no further development is planned.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.